Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


AstraZeneca Breast Cancer Study Locator Service 1-877-400-4656
az-bcsl@careboxhealth.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Back

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Recruiting

Open to: ALL

Age: 18.0 - 130.0

London Glasgow, Scotland Newcastle Upon Tyne

Medical Conditions

Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2022 Feb 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive AZD9574 orally.

Intervention Arm Group : Module 1 Part A: Dose escalation;Module 1 Part B: Dose expansion;Module 2 Part A: Dose escalation;Module 4 Part A: Dose escalation (AZD9574 + T-DXdat);Module 5 Part A : Dose escalation (AZD9574 + Dato-DXd);

Intervention Type : DRUG
Intervention Description : Participants will receive temozolomide orally.

Intervention Arm Group : Module 2 Part A: Dose escalation;

Intervention Type : DRUG
Intervention Description : Participants will receive \[11C\]AZ1419 3391 intravenously.

Intervention Arm Group : Module 3 Panel 1: AZD9574 monotherapy (Sweden only);Module 3 Panel 2: AZD9574 + TMZ (Sweden only);Module 3 Panel 3: AZD9574 monotherapy (Sweden only);

Intervention Type : DRUG
Intervention Description : Participants will receive Dato-DXd intravenously.

Intervention Arm Group : Module 5 Part A : Dose escalation (AZD9574 + Dato-DXd);

Intervention Type : DRUG
Intervention Description : Participants will receive T-DXd intravenously.

Intervention Arm Group : Module 4 Part A: Dose escalation (AZD9574 + T-DXdat);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    London
    EC1M 6BQ
  • Research Site
    Glasgow, Scotland
    G12 0YN
  • Research Site
    Newcastle Upon Tyne
    NE7 7DN

AstraZeneca Breast Cancer Study Locator Service 1-877-400-4656
az-bcsl@careboxhealth.com


AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05417594
Last updated 24 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top